Metformin's effect on aging markers in prediabetic individuals: RCT protocol description
This document describes the protocol for a randomized controlled trial investigating whether metformin treatment affects aging-related biomarkers in prediabetic subjects from North India. The study planned to compare 6 months of metformin versus placebo and measure telomere length, telomerase activity, and expression of longevity-related genes (SIRT1, p66Shc, p53, mTOR) in blood cells. No results or outcome data are reported.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 24, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 6 months
- Population
- Pre-diabetic individuals from North India
- Primary outcome
- Leukocyte telomere length and telomerase activity
- Effect size
- —
- Significance
- Not reported
- Journal
- Diabetes Foundation, India
- Published
- Dec 24, 2025
Sources
Primary source
- Diabetes Foundation, India ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.